Treating Stroke and Other Diseases Without Inhibiting N-Type Calcium Channels
AssigneesArbor Vita Corporation, NoNO Inc.
InventorsMichael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
Life of this patent
Estimating the term…
Abstract
The invention provides methods for treating stroke and compositions for use in the same. The methods employ a chimeric peptide of an active peptide and an internalization peptide. The internalization peptide is a tat variant that promotes uptake of itself and a linked active peptide into a cell without substantial binding to N-type calcium channels. Use of the tat variant allows treating of stroke free of certain side effects associated with binding to N-type calcium channels. Tat variant peptides can also be linked to other active agent for use in treating other diseases.
Claims12
1-34. (canceled)
An isolated chimeric agent, wherein the chimeric agent comprises an active agent and an internalization peptide that promotes uptake of the chimeric agent into cells, wherein the internalization peptide is a variant of the tat peptide YGRKKRRQRRR (SEQ ID NO:1) that has reduced capacity to bind to an N-type calcium channel relative to the tat peptide and the variant has an amino acid sequence comprising FGRKKRRQRRR (SEQ ID NO:135).
37-40. (canceled)
An isolated internalization peptide having an amino acid sequence comprising FGRKKRRQRRR (SEQ ID NO:135).
44-46. (canceled)
(canceled)
In a chimeric agent comprising an internalization peptide linked to an active agent, the improvement wherein the internalization peptide has an amino acid sequence comprising FGRKKRRQRRR (SEQ ID NO:135).
50-51. (canceled)
Dependencies are inferred from the claim text.